Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc, GlaxoSmithKline Capital plc, and GlaxoSmithKline Capital Inc. is dated March 18, 2013. The report serves to incorporate specific exhibits by reference into the registrants' Registration Statement on Form F-3 (File No. 333-172621). The filing relates to a corporate financing transaction rather than a standard periodic financial report.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the legal documentation required for a debt issuance.
Material Changes and Transaction Details
The primary material event disclosed is the execution of an underwriting agreement dated March 13, 2013, involving GlaxoSmithKline Capital Inc. and major financial institutions including Deutsche Bank Securities Inc., Goldman, Sachs & Co., J.P. Morgan Securities LLC, and UBS Securities LLC. Additionally, a First Supplemental Indenture dated March 18, 2013, was executed with Law Debenture Trust Company of New York.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The document is a procedural filing to update a registration statement with legal opinions and transaction agreements.
Key Facts for Investor Verification
- The filing incorporates an Underwriting Agreement dated March 13, 2013, indicating a new debt offering.
- A First Supplemental Indenture was executed on March 18, 2013, modifying existing debt terms or establishing new ones.
- Legal opinions regarding the transaction were provided by Cleary Gottlieb Steen & Hamilton LLP.
- No financial performance data is included in this specific Form 6-K; investors should refer to the referenced Form F-3 or recent 20-F filings for financial metrics.